Standout Papers
Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
2009
Transition from inflammation to proliferation: a critical step during wound healing
2016 Standout
Risk factors for functional limitations in patients with long‐standing ankylosing spondylitis
2005
Clinical Features and Associated Systemic Diseases of HLA-B27 Uveitis
1996
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
2004
Cytokines in inflammatory bowel disease
2014 Standout
Non-motor symptoms of Parkinson's disease: diagnosis and management
2006 Standout
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
2004
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care
2004
Rheumatoid arthritis
2018 Standout
Chemistry of peptides associated with MHC class I and class II molecules
1995
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: A prerequisite for local androgen deficiency
2005
Gastrointestinal dysfunction in Parkinson's disease
2003 Standout
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system
2003
Interactions between the microbiota, immune and nervous systems in health and disease
2017 Standout
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
2005
Rheumatoid arthritis
2016 Standout
Review article: infliximab therapy for inflammatory bowel disease – seven years on
2006
The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research
2008
Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial
2005
Ulcerative Colitis
2011 Standout
The Effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
2004
Anti-TNF-α Antibody Therapies in Autoimmune Diseases
2006
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
2004
Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society
2007 Standout
Role of interleukin‐6 in stress, sleep, and fatigue
2012
Differentiating the efficacy of the tumor necrosis factor inhibitors
2005
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Extraintestinal manifestations of inflammatory bowel disease
2008
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
2007
Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
2002
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
2006
Juvenile idiopathic arthritis
2007 Standout
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents
2007
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes
2007
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept
2005
Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease
2007
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trial
2006
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
2002
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
2006
Anti-TNF-alpha therapy in ankylosing spondylitis
2006
Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis
2004
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Psoriasis
2021 Standout
Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitis
2003
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
2007
Patient-assessed health in ankylosing spondylitis: a structured review
2005
Repertoire of microglial and macrophage responses after spinal cord injury
2011 Standout
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
2006
An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice
2011
IL-6 as a keystone cytokine in health and disease
2015 Standout
Assessment of enthesitis in ankylosing spondylitis
2003
ASAS/EULAR recommendations for the management of ankylosing spondylitis
2005
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
2003
Neutrophils and immunity: challenges and opportunities
2006 Standout
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Ulcerative colitis
2012 Standout
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two
2008
Signalling pathways of the TNF superfamily: a double-edged sword
2003 Standout
Anti–tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy
2005
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
2004
Six months open label trial of leflunomide in active ankylosing spondylitis
2004
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
2007
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis
2005
Ankylosing spondylitis
2007 Standout
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
2005
Familial Mediterranean fever responds well to infliximab: single case experience
2005
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study
2004
A systematic medline analysis of therapeutic approaches in ankylosing spondylitis
2009
Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: Results of a multicenter, randomized study
2011
Effect of Solar Particle Event Radiation on Gastrointestinal Tract Bacterial Translocation and Immune Activation
2011 StandoutNobel
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
2003
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
2003
TNFα blockade in human diseases: An overview of efficacy and safety
2007
European evidence-based Consensus on the management of ulcerative colitis: Special situations
2008
Efficacy of infliximab in resistant psoriatic arthritis
2003
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis
2005
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab
2007
Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis
2004
Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease
2007
How to diagnose axial spondyloarthritis early
2004
Ulcerative colitis
2016 Standout
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
2007
The role of B cells in rheumatoid arthritis
2003
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis
2003
HLA–B27–restricted CD8+ T cell response to cartilage‐derived self peptides in ankylosing spondylitis
2005
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
2006
The juvenile-onset spondyloarthritides
2002
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))
2004
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
2010 Standout
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system
2004
Non-motor features of Parkinson disease
2017 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis
2005
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
2008
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial
2006
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab
2005
Safety of Tumour Necrosis Factor-?? Antagonists
2004
Protective and pathogenic functions of macrophage subsets
2011 Standout
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients
2004
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Quality criteria were proposed for measurement properties of health status questionnaires
2006 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
2004
Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis
2005
The comparative effectiveness of tumor necrosis factor–blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six‐month, longitudinal, observational, multicenter study
2005
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists
2005
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
2005
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
2015
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
2009 Standout
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
2003
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging study
2006
Assessments in ankylosing spondylitis
2006
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
2005
Lupus Nephritis Improvement After Anti‐tumor Necrosis Factor Alpha Monoclonal Antibody (Infliximab) Treatment for Crohn's Disease: A Case Report
2004
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study
2005
Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro
2008
The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?
2005 Standout
Wound repair and regeneration: Mechanisms, signaling, and translation
2014 Standout
Autoimmunity and Anti-TNF-α Agents
2005
The Complex Role of Estrogens in Inflammation
2007 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
2005
Psoriasis Pathogenesis and Treatment
2019 Standout
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
2007
Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
2006
Therapies for axial disease in psoriatic arthritis. A systematic review.
2006
T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus
2001 StandoutNobel
Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing
2017 Standout
Update on Spondyloarthropathies
2002
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
2008
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes.
2005
Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop
2005 Standout
The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment
2015
The Immune Response in Tuberculosis
2013 Standout
Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
2004
TNF‐mediated inflammatory disease
2007 Standout
Etanercept therapy in patients with autoimmunity and hepatitis C
2003
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
2017
Critical Role of the Carboxyl Terminus of Proline-rich Tyrosine Kinase (Pyk2) in the Activation of Human Neutrophils by Tumor Necrosis Factor
2002
Macrophage plasticity and polarization in tissue repair and remodelling
2012 Standout
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
2008
Reactivation of Latent Tuberculosis Infection in TNF-Deficient Mice
2003
Works of H. Kellner being referenced
Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial
2003
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
2010
Evaluation of a novel 7‐joint ultrasound score in daily rheumatologic practice: A pilot project
2009
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
2002 Standout
The pathogenetic aspects of spondyloarthropathies from the point of view of HLA-B27
1992
Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years
2005
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
2004
[Reversible esophageal dysfunction as a side effect of levodopa].
1996
Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen
2002
A patient-derived cytotoxic T-lymphocyte clone and two peptide-dependent monoclonal antibodies recognize HLA-B27-peptide complexes with low stringency for peptide sequences
1996
FRI0199 Rituximab in Combination with Leflunomide: Results from A Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study)
2016
A monoclonal antibody that recognizes HLA-B27 in the context of peptides.
1994